Media Release

Zurich, Switzerland - September 26, 2014

Nobel Biocare benefits from a positive result of a mutual agreement procedure among two tax authorities

Nobel Biocare obtained a favorable answer from a mutual agreement procedure among two tax authorities which will allow for an immediate release of a tax provision in the amount of approximately EUR 9.6 million. While this amount will be fully recognized in the tax line of the profit and loss statement in the third quarter 2014, it will have no cash impact.

Nobel Biocare has been included in a mutual agreement procedure with regards to its filed level of taxable profits for the fiscal years spanning 2009 to 2013. The original assessment of one of the authorities would have led to a significantly increased taxable profit level which would have resulted in additional income taxes. Based on the above mentioned assessment and applying best estimate, the company had recognized an income tax provision.

The Company has now received notification that the tax authorities have followed Nobel Biocare's position and confirmed that no adjustment of the taxable profit for the fiscal years spanning 2009 to 2013 will be made. As a result, the tax provision of approximately EUR 9.6 million will be immediately released.

Contact information:

Süha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com

Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in the field of innovative implant-based dental restorations. The company's portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, Brånemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 566.8 million in 2013. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.


Media Release (PDF)



Provider
 Channel
 Contact
Tensid Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50